Allergan Shows Off Phase III Migraine Data Post author:Sam Post published:February 5, 2018 Post category:BioPharma The ACHIEVE I study included 1327 U.S. adult patients. Source: BioSpace You Might Also Like Never Say Never: Why Taking Out Bristol-Myers Squibb Could Boost Pfizer's Value by $5 Billion March 27, 2017 Verastem Soars as Blood Cancer Drug Succeeds in Phase III Study September 5, 2017 Pfizer Quietly Takes 16.4% Stake in This SoCal Medtech Firm February 13, 2017
Never Say Never: Why Taking Out Bristol-Myers Squibb Could Boost Pfizer's Value by $5 Billion March 27, 2017
